Valuation: MannKind Corporation

Market Cap 1.26B 1.11B 1.02B 942M 1.79B 121B 1.82B 12.18B 4.78B 59.37B 4.74B 4.64B 204B P/E 2026 *
-143x
P/E 2027 * 29x
Enterprise Value 1.26B 1.11B 1.02B 942M 1.79B 121B 1.82B 12.18B 4.78B 59.37B 4.74B 4.64B 204B EV / Sales 2026 *
2.73x
EV / Sales 2027 * 2.42x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day-1.21%
1 week-9.51%
Current month-3.99%
1 month+11.75%
3 months+59.14%
6 months-29.12%
Current year-27.87%
1 week 3.98
Extreme 3.9812
4.41
1 month 3.7
Extreme 3.7
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

109,337 0.0354%
05-19Free

Head of Human Resources

33,898 0.0110%
05-19Other

Chairman

99,337 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%-9.51%+8.49%-1.45% 1.26B
+1.84%-0.66%+59.82%+94.48% 54.88B
+0.37%-5.71%+57.28%+130.42% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+0.28%+2.49%+36.52%-27.60% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -1.24%-1.20%+46.85%+183.27% 24.28B
Weighted average by Cap. -0.49%-1.49%+50.18%+172.12%

Financials

2026 *2027 *
Net sales 463M 405M 373M 345M 655M 44.15B 666M 4.46B 1.75B 21.75B 1.74B 1.7B 74.77B 522M 456M 421M 389M 737M 49.74B 750M 5.03B 1.97B 24.51B 1.96B 1.92B 84.25B
Net income 72K 62.98K 58.09K 53.65K 102K 6.87M 104K 694K 273K 3.38M 270K 264K 11.63M 56.82M 49.7M 45.84M 42.34M 80.34M 5.42B 81.69M 548M 215M 2.67B 213M 209M 9.18B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
10/07/26 US$4.090 -1.21% 4,250,071
09/07/26 US$4.140 -2.59% 3,358,418
08/07/26 US$4.250 +0.71% 6,892,667
07/07/26 US$4.220 -1.17% 3,394,138
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.090USD
Average target price
7.594USD
Spread / Average Target
+85.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock